Dupilumab (Dupixent) for the treatment of eczema in teenagers
In 2019, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether dupilumab has any advantages or disadvantages compared to optimized individual treatment for moderate to severe in young patients aged 12 years and over who are able to have systemic treatment.
The manufacturer didn't provide any suitable studies involving teenagers. So IQWiG used a study involving adults instead, specifically looking at the results related to people between the ages of 18 and 39. In this age group, 52 people were given dupilumab for about half a year (300 mg of dupilumab every 2 weeks) and 189 were given a placebo (fake medication). In addition, both groups had treatment with glucocorticoid (steroid) creams. If their symptoms got worse, the treatment was individually adjusted further. The study included only people who had had moderate to severe for at least three years.